52128-35-5

Basic information

• Product Name: Trimetrexate
• Synonyms: Trimetrexate;5-Methyl-6-(3,4,5-trimethoxyanilinomethyl)quinazoline-2,4-diamine;5-Methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]-2,4-quinazolinediamine;CI-898;2,4-Quinazolinediamine, 5-methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]-;5-Methyl-6-{[(3,4,5-triMethoxyphenyl)aMino]Methyl}quinazoline-2,4-diaMine
• CAS NO: 52128-35-5
• Molecular Formula: C₁₉H₂₃N₅O₃
• Molecular Weight: 369.4176
• Mol File: 52128-35-5.mol
• Article Data: 2

Chemical Properties

• Melting Point: 215-217 °C
• Boiling Point: 647 °C at 760 mmHg
• Flash Point: 345.1 °C
• Appearance: /
• Density: 1.305g/cm³
• Vapor Pressure: 1.34E-19mmHg at 25°C
• Storage Temp.: 2-8°C(protect from light)
• PKA: 8.09±0.30(Predicted)
• CAS DataBase Reference: Trimetrexate(CAS DataBase Reference)
• NIST Chemistry Reference: Trimetrexate(52128-35-5)
• EPA Substance Registry System: Trimetrexate(52128-35-5)

Safety Data

• Hazardous Substances Data: 52128-35-5(Hazardous Substances Data)

Usage

Description

Trimetrexate (TMQ) has been approved for the treatment of Pneumocystis carinii in patients with AIDS and also exhibits antiprotozoal activity against Trypanosoma cruzi . The drug is available as a single-ingredient medication, but it can be administered along with folinic acid in much the same way that methotrexate is administered with calcium leucovorin in cancer chemotherapy. Trimetrexate is a derivative of methotrexate.

Uses

Different sources of media describe the Uses of 52128-35-5 differently. You can refer to the following data:
1. Antineoplastic.
2. Trimetrexate is an FDA-approved drug which selectively inhibits Streptococcus mutans through targeting dihydrofolate reductase (DHFR).

General Description

The drug is available as a lyophilized powder in 5- or 30-mgvials for IV use. The drug is used to treat colorectal cancer,head and neck cancer as well as NSCLC. The mechanism ofaction of trimetrexate involves folate antagonism and inhibitionof thymidylate synthesis. Trimetrexate does not formintracellular polyglutamate adducts as does methotrexateand other related compounds. Resistance can occur by increasedexpression of the target enzyme, decreased bindingaffinity for the target enzyme, or decreased intracellulardrug transport. Trimetrexate is administered only by the IVroute and distributed throughout the body with extensivebinding to plasma proteins. The major catabolic pathwaysinvolve O-demethylation followed by glucuronide conjugation.The drug interaction and toxicity profiles are similar tothose for methotrexate.

Mechanism of action

Trimetrexate is considered to be a nonclassical folate antagonist, whereas methotrexate, the structurally similar analogue of TMQ, is a classical folate antagonist. The difference between these two drugs is that methotrexate, with its polar glutamate side chain, is transported into the cell via a carrier-mediated transport system, whereas TMQ, without the glutamate moiety, is absorbed by the cell via a passive diffusion. Once in the cell, TMQ inhibits DHFR. Trimetrexate binds to Pneumocystis cari nii DHFR 1,500 times more strongly than trimethoprim and somewhat more strongly than methotrexate. It also has been reported that TMQ readily enters the P. carinii cell because of the lipophilic nature of this drug. Methotrexate and leucovorin are not able to enter the cell, however, because the cell membrane of P. carinii does not possess the transporter protein.

Clinical Use

Trimetrexate, when combined with the cytoprotective agent leucovorin, is more effective and better tolerated than pentamidine in the treatment of PCP. Because the first- and second-line agents are successful in only 50 to 75% of these cases, and because adverse reactions severely limit the use of some of the older agents, TMQ may offer some advantages in treatment. Trimetrexate is administered by IV infusion over 60 to 90 minutes and should be combined with the cytoprotective drug leucovorin. The leucovorin protects against bone marrow suppression and against renal and hepatic dysfunction. Leucovorin administration should continue for 72 hours after the last dose of TMQ. Additionally, TMQ has been reported to be effective in the treatment of Chagas' disease.

InChI:InChI=1/C19H23N5O3.3ClH/c1-10-11(5-6-13-16(10)18(20)24-19(21)23-13)9-22-12-7-14(25-2)17(27-4)15(8-12)26-3;;;/h5-8,22H,9H2,1-4H3,(H4,20,21,23,24);3*1H

Upstream product

• 253-82-7 quinazoline 
• 24313-88-0 3,4,5-Trimethoxyaniline 
• 18917-72-1 2,4-diamino-5-methyl-6-quinazolinecarbonitrile 

Relevant articles and documents

Thermally stable trimetrexates and processes for producing the same

The present invention provides for thermally stable forms of 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline, or trimetrexate. A crystalline 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline monohydrate, or trimetrexate monohydrate, belonging to the space group P+E,ovs 1+EE (#2) and having a triclinic cell with dimensions of about a=7.699 ANGSTROM , b=9.606 ANGSTROM and c=13.012 ANGSTROM is disclosed. A novel Schiff base compound, 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyphenylimino)-methinyl]quinazoline, is also disclosed. The present invention further provides novel methods of producing stable trimetrexate free base compounds, including crystalline trimetrexate monohydrate. The crystalline monohydrate form provides increased stability over the anhydrous form.